J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) — shareholding pattern, promoter holding, financials and share price
About J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM)
J B Chemicals & Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as JBCHEPHARM and on the BSE under scrip code 506943. Its ISIN is INE572A01036.
J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]
J.B. Chemicals & Pharmaceuticals Limited is a leading pharmaceutical company established in 1976, heavily engaged in the manufacture and marketing of diverse pharmaceutical formulations, herbal remedies, and APIs.
The company continues to be one of the fastest growing organizations in the Indian pharmaceutical market, demonstrating superior performance with notable growth in key brands such as Cilacar, Sporlac, and Razel.
Listed peers in Pharmaceuticals: Ipca Laboratories Ltd, Ajanta Pharma Ltd, Glaxosmithkline Pharmaceuticals Ltd, Gland Pharma Ltd, Emcure Pharmaceuticals Ltd, Wockhardt Ltd.
Valuation & Returns
10 Jul 2026At ₹2,449 a share on 10 Jul 2026, J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) was valued at a price-to-earnings ratio of 55.42x against an industry P/E of 36.41x and a price-to-book of 9.45x on a book value of ₹259.05 per share as of Mar 2026. Solomo computes return on equity of 17.06% and return on capital employed of 23.01% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 55.42x
- Industry P/E
- 36.41x
- P/B
- 9.45x
- EPS (TTM)
- ₹44.19
- Book value / share
- ₹259.05
- ROE
- 17.06%
- ROCE
- 23.01%
- ROA
- 14.28%
- Debt / equity
- 0x
- Dividend yield
- 1.18%
- EBITDA margin
- 27.49%
- 52-week range
- ₹1,603.05 – ₹2,473.65
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) reported revenue of ₹4,148 crore, net profit of ₹709 crore and earnings per share of ₹44.19. That compares with revenue of ₹3,918 crore and net profit of ₹660 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹904 crore and net profit ₹101 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2,424 | 3,149 | 3,484 | 3,918 | 4,148 |
| Net profit (₹ cr) | 386 | 410 | 553 | 660 | 709 |
| EPS (₹) | 24.93 | 26.48 | 35.61 | 42.37 | 44.19 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 13.97% | 15.51% | 10.49% | 5.87% |
| Profit growth | 16.32% | 8.56% | 20.12% | 7.56% |
| Stock price CAGR | 34% | 21% | 23% | 46% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 48.8% of J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) (up 1.25 pp QoQ), foreign institutional investors (FII) hold 16.33% and domestic institutional investors (DII) hold 21.38%. Market capitalisation was ₹39,321 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Mar 2026: KOTAK MIDCAP FUND 4.4%, AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUND A/C AXIS SMALL CAP FUND 3.81%, CANARA ROBECO MUTUAL FUND A/C CANARA ROBECO SMALL CAP FUND 2.17%, GOVERNMENT PENSION FUND GLOBAL 1.84%, NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHARMA FUND 1.6%, SMALLCAP WORLD FUND, INC 1.3%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 48.8% | - | 16.33% | 21.38% | 51.2% |
| Dec 2025 | 47.55% | - | 14.88% | 23.36% | 52.45% |
| Sep 2025 | 47.56% | - | 15.3% | 22.83% | 52.44% |
| Jun 2025 | 47.73% | - | 17.77% | 19.63% | 52.27% |
| Mar 2025 | 47.84% | - | 18.3% | 18.72% | 52.16% |
| Dec 2024 | 53.66% | - | 14.64% | 16.41% | 46.34% |
| Sep 2024 | 53.74% | - | 13.63% | 16.81% | 46.26% |
| Jun 2024 | 53.77% | - | 12.17% | 17.62% | 46.23% |